Marta AlonsoSara BecerrilMaria C. OchoaCarlos CentenoMaite HerráizJosé Vicente Fernández-MonteroCarlos AlfaroDomingo Francisco Javier Díez MartínezJuan P de TorresAdriano GuarnieriLeyre AguadoJavier CortesMaría CollantesSergio RecaldeJavier J. ZuluetaJosé María López-PicazoJavier A CienfuegosCirino BottaPedro AzcárateManuel F LandechoGustavo VinagreMarta FerrerLuis M SeijoPatricia MaisoPablo Daniel DomínguezRamón ManguesGabriel ReinaJose Ramon Perez-ValdiviesoBruno SangroJosé Manuel AzconaAna AlfonsoJuan José Mata MolanesLaura Moreno NarroCristina AzconaJavier SerranoB OlartecoecheaJosepmaria ArgemíJ LeivaJuan Luis AlcazarJosé Ramón Azanza
P108
Effect of TTFields (150 kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-10 Brain Metastases Following Radiosurgery (METIS)A Study to Determine Dose and Tolerability of CC-220 Monotherapy, in Combination With Dexamethasone, and in Combination With Dexamethasone and Daratumumab or Bortezomib in Subjects With Relapsed and Refractory Multiple Myeloma (MM)A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaEvaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple MyelomaAntithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic SyndromeGEM05 for Patients With Multiple Myeloma More Than 65 Years OldThird International Study on Mechanical VentilationEfficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients.The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk SubjectsA Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular AlterationsAn Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid TumorsNab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)Clinical Trial to Evaluate the Efficacy and Safety of the Transarterial Supraselective Embolization of the Prostate to Treat the Urinary Symptoms.Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 in the Treatment of Anemia Associated With Chronic Kidney Disease (SWEEP)Efficacy Study of Combined Treatment With Uric Acid and rtPA in Acute Ischemic StrokeEfficacy and Safety Study of bb2121 Versus Standard Triplet Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)Patient-reported Outcome Scale in Acute PancreatitisNon-Interventional Study in Patients With Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL) to Investigate the Association of Lenalidomide With Tumor Flare Reaction and High Tumor BurdenAEDV Registry of Primary Cutaneous LymphomaGolimumab Trough Levels in Patients With Ulcerative ColitisAccuracy for Predicting Deep Submucosal InvasionTreatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 YearsA Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar IchthyosisSafety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to TherapyDNX-2440 Oncolytic Adenovirus for Recurrent GlioblastomaA Study to Observe Vedolizumab Outcomes in Real-world Biologic Ulcerative Colitis (UC) and Crohn's Disease (CD) ParticipantsVedolizumab in the Prophylaxis of Intestinal Acute Graft vs Host Disease in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) TransplantationA Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM)Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB)Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II StudyFollow-up in Gynecological Cancer SurvivorsComparison of Weight Loss Induced by Bariatric Surgery vs Conventional TreatmentClinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical CarcinomaBIOFLOW-III All-comers Orsiro Safety and Performance RegistryCorrelation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal CancerAtypical Hemolytic-Uremic Syndrome (aHUS) RegistryEfficacy and Tolerability of a Topical Microemulsion in Patients With Allergic Rhinitis Due to Sensitization to PollenChemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVEStudy of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
P6153
Q23015897-941bd61d-4b4a-4e26-44f4-981c0ad107b3Q38319149-90A2F45B-F53F-4AB0-A3D4-FA13A5F53468Q40724836-671AFA78-CC50-4ABB-B5B0-73B7A0348309Q41522767-FE73BE39-9EBE-43BB-8703-D59D5203FA29Q41593817-62020235-4b8a-80cd-3fb0-c56050f5fa1bQ42280769-8FEB41B2-1625-4940-98DF-E9E9183B152DQ42417758-4EA38981-DF5C-4A45-9521-1471C9005FCEQ42541154-408016DE-14DE-4746-9E09-DA53CAB8DCD3Q43014233-ED48134F-D1AD-4BFE-AEE3-7DF2AF0F8293Q43059929-216F9674-7017-4EE1-A8A3-0EF3D8F2ED33Q43090554-1D44C304-37E9-4898-935C-04E3C3C89BBAQ43114235-20DAFF98-B49D-46FA-96C5-336BB3BB4D52Q43123199-B4CA5152-03F1-4CC5-A542-4FB89B8AB1A0Q43515628-9AEB96B1-52C2-4D24-BA64-B134D1B630F9Q43870372-A6F34C39-8F42-4B9C-BEE0-A6CA4F3E4FABQ43870372-EB104C91-5E62-4E11-9C27-9B2720AB286FQ44110494-8F91AA73-4946-40B9-AFD7-479F9528731FQ44110494-DAFC591C-5A3E-4402-B3C6-A0FA598C4C37Q45711878-E20737AD-4197-4C34-AE14-FC95745EDAAEQ45921604-CCD26400-7685-43AA-9599-F1432619628DQ46707566-55B37BFB-CB2F-4489-B31E-D9E472C118B9Q46707566-58337678-D8D0-4BDD-84F1-ED0C5AEF8653Q47503297-7D72C1FC-14DD-42AB-8A77-FBD19038E33AQ49762044-932F17D3-86B2-4924-8EFC-C0AA9824FC49Q50214534-FE7F6FA7-BEEA-479F-9C74-331D9C59370CQ53130305-1CEDA428-4219-4046-B8F0-09285F8F225BQ53140836-BB2A0693-C91E-4921-8AD7-AB46E16B919CQ55172775-35DA7D00-CD49-47C4-99E5-05A1F40640A1Q55603191-75D681BA-2F4E-42BE-9CCA-D9FF8161B8AAQ56065745-A5AD0EC8-DA70-4629-B0D8-43A9E6D660D6Q56090614-E483C722-0602-4872-BE61-628299CE83C1Q56418908-F72B911A-3A80-48EB-B5AE-DD49E0F4FE62Q56556351-769B16B2-BECC-420D-A137-9E7B943B74EEQ56811249-6F4FC480-0848-4C45-8FA3-32B764A9AB5FQ57176687-E34A9ABF-D8A5-40AD-B6BA-F411EAC6750EQ57176692-B7F8527C-DF84-4EB7-8C7E-866608D560E7Q57176692-DD1CC936-E065-4C70-A89F-74F5F15F42A4Q57329367-0D6B84E1-8DA1-4A2F-972F-A052B12252B8Q57615014-EB4FBDB4-2E5A-401D-AE4C-4D3888CD5979Q57689857-F400A832-829F-488A-9DE8-A30D99877084
P108
Q61862161-33CA180C-39D2-4A5A-8CC6-8A6C577F3C25Q61862177-C839F57A-4A3B-44B6-A593-3DFCDB5CE144Q61862227-2EF24FB8-296A-4359-9F5E-C228CC35C51EQ61864842-5856B212-DF49-437F-82E2-3FC870FCA59DQ61918239-1BAB57BD-DC74-4855-BC3D-F90BBFB498C2Q61924901-78663C0B-C655-485E-AFEE-26BBFD2AB760Q61936877-EAFE20FD-8319-4F5B-BCA0-E60F092C6233Q61939181-1BE3E756-934A-48A0-9A6B-4D63B78A5C95Q61974963-AEE932CE-48B9-4F59-AF56-5FE6AB412A67Q61975328-E7033756-3DDA-4E77-883D-47B65F9A190AQ61975539-F624ED42-C0C5-4BF4-B03F-B4B003853F5CQ61975843-3542AA70-7BDD-4979-882E-73A1D1871863Q61975936-02DF2785-2BA8-4085-9F87-32CA7CFC87E9Q61980688-CAD1A031-ED30-4A9F-A3D7-251B557CD151Q61981513-88B32A71-1C2C-4A1F-8A92-897ED9297B90Q62025368-0BFEFE12-8FC4-4BBD-BE82-6710436CBFF5Q62025451-B15D6B1F-0322-4913-81B0-0FAA3B4A0E67Q62025694-E2388054-AC53-493F-908B-18476E87ED75Q62025751-6F2D5DB2-EFB1-4D53-A170-61185D323E10Q62031098-2631344E-18C8-4365-9751-F4AE7BD73AE8Q62034167-AF73DF21-3D71-402F-822B-5F2D2A4253ACQ62034766-F0F1E6E7-3401-4DEF-9C92-CEB7602D7281Q62035253-77DF2837-FD79-401E-B097-A368849F9145Q62040091-1D3CFEAC-891E-4E10-9484-550D83208EE4Q62041245-BB798655-0E70-456D-A022-6A5132973F3BQ62042078-6057E495-9D68-44D8-9AC7-089B37F756A9Q62062643-943520E3-914F-41BA-981F-E2ECAEE3200AQ62062674-80524779-B1ED-46D7-9137-363E03E52576Q62812912-1E59F351-F71A-422E-908A-29F9C854DFF1Q62814902-59649B29-7378-495A-8B56-2C31F54DBF05Q62817541-2A0C23A5-DF2B-4D93-AA86-FA57351EAE34Q62818010-9A0D58F9-1D43-4A1D-9962-CB46FFA1FBBDQ63316410-6E29A0C0-90F0-4F3D-998D-4A77894CEFBAQ63317365-6EDECE76-7A02-411B-BACF-63B5951570B6Q63319212-AA39D357-ED39-4408-BEB9-EBED7E868E92Q63319869-E82BAEB4-A314-41BC-BD8D-3C82042B92DCQ63319884-D868ED64-0B5D-4EC4-AC39-1358ACE80366Q63320212-8E0EA638-C5D5-4488-9144-2AFA89405C3FQ63320422-F2440A9D-F3F5-4D6A-A3B8-3B800723B5D0Q63322078-9C806579-FC1C-4585-A444-1032F8AB6AFA
P6153
description
Edificio protegido en Pamplona
@es
Gebäude in Spanien
@de
eraikin babestua Iruñean
@eu
university hospital in Pamplona, Spain
@en
בית חולים בספרד
@he
name
Clínica Universidad de Navarra
@en
Clínica Universidade de Navarra
@pt
Clínica Universitaria
@es
Klinika Uniwersytetu Nawarry
@pl
Nafarroako Unibertsitatea Klinika
@eu
type
label
Clínica Universidad de Navarra
@en
Clínica Universidade de Navarra
@pt
Clínica Universitaria
@es
Klinika Uniwersytetu Nawarry
@pl
Nafarroako Unibertsitatea Klinika
@eu
altLabel
CUN
@en
CUN
@es
Clinica Universidad de Navarra
@en
Clinica Universidad de Navarra
@es
Clinica Universitaria de Navarra
@es
Clinica Universitaria de Navarra
@eu
Clínica Universitaria de Navarra
@es
Clínica Universitária de Navarra
@pt
Klinika Unibertsitarioa
@eu
Nafarroako Klinika Unibertsitarioa
@eu
prefLabel
Clínica Universidad de Navarra
@en
Clínica Universidade de Navarra
@pt
Clínica Universitaria
@es
Klinika Uniwersytetu Nawarry
@pl
Nafarroako Unibertsitatea Klinika
@eu
P214
P227
P244
P950
P131
P17
P1890
P213
0000 0001 2191 685X
P214
P227
P2427
grid.411730.0
P244
P3500
P373
Clínica Universidad de Navarra
P571
1962-01-01T00:00:00Z